Abstract:Accumulating studies have indicated that N6-methyladenosine (m6A) plays an important role in acute myeloid leukaemia (AML). However, little is known about the m6A methylome at a transcriptome-wide scale in AML patients. We obtained three pairs of bone marrow (BM) samples from cytogenetically normal AML patients at the timepoints of diagnosis (AML) and relapse (R_AML) and three BM samples from healthy donors used as normal controls (NCs). Methylated RNA immunoprecipitation next-generation sequencing (MeRIP-Seq) was conducted to identify differences in the m6A methylomes between AML and NC and between R_AML and AML. We identified a total of 11,076 and 11,962 differential m6A peaks in AML and R_AML group, respectively. These dysregulated m6A peaks were detected on all chromosomes, especially chr1, chr19 and chr17, and were mainly enriched in 3' untranslated regions, stop codon and coding sequence regions. Moreover, GO and KEGG analyses indicated that m6A -modified genes were significantly enriched in cancer-related biological functions and pathways. Additionally, we identified a link between the m6A methylome and RNA transcriptome via combined analyses of MeRIP-seq and RNA-seq data. In addition, 5 genes, HSPG2, HOMER3, TSPO2, CXCL12 and FUT1 regulated by m6A modification potentially, were shown to be related to the prognosis of AML patients. Additionally, we detected the mRNA expression of major m6A regulators and potential target mRNA on the leukemogenesis and found that the expression of IGF2BP2, HSPG2 and HOMER3 were upregulated in AML at the time of diagnosis. Moreover, their expression became downregulated after remission and then elevated again at relapse. Our study provides the first data on the differential m6A methylome in AML patients during initial diagnosis and relapse. This study demonstrates a novel relationship between m6A modification and AML relapse and paves the way for further studies aimed at elucidating the epigenic mechanisms involved in the relapse of AML.

The Gene Expression Level of M6a Catalytic Enzymes is Increased in ETV6/RUNX1-positive Acute Lymphoblastic Leukemia.

Distinct Microrna Expression Profiles In Acute Myeloid Leukemia With Common Translocations

RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia

Clinical Significance of Monitoring ETV6-RUNX1 Fusion Gene Expression in Children with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Prevalence of Etv6-Runx1 Fusion Gene in Children with Acute Lymphoblastic Leukemia in China

Gene Expression Prognostic of Early Relapse Risk in Low‐risk B‐cell Acute Lymphoblastic Leukaemia in Children

ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis

Germline Genetic Variation in Etv6 and Predisposition to Childhood Acute Lymphoblastic Leukemia

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia

ETV6-ACSL6 Fusion Gene in Myeloid Neoplasms: Clinical Spectrum, Current Practice, and Outcomes

Expression Level of GAS6-mRNA Influences the Prognosis of Acute Myeloid Leukemia Patients with Allogeneic Hematopoietic Stem Cell Transplantation

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

Characterization of m6A regulator‐mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia

Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia

Identification of diagnosis and prognosis gene markers in B-ALL with ETV6-RUNX1 fusion by integrated bioinformatics analysis

Characterization of leukemias with ETV6-ABL1 fusion

Dynamic alterations of the transcriptome-wide m6A methylome in cytogenetically normal acute myeloid leukaemia during initial diagnosis and relapse

A Six Gene Expression Signature Defines Aggressive Subtypes and Predicts Outcome in Childhood and Adult Acute Lymphoblastic Leukemia.

ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression

KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs